mRNA platform
[용어속성] Term
Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics
Review
[키워드] approval
approved
candidate
clinically
COVID-19
delivery
develop
disease
Efficacy
Emergency use
evaluated
gene editing
genetic disease
Genetic diseases
global pandemic
issue
lesson
Lipid
Lipid nanoparticles
LNP
mRNA
mRNA platform
mRNA-based
mRNA-based therapeutics
mRNA-based vaccine
mRNA-LNP
nanoparticle
Onpattro
Pharmaceutics
platform
prophylactic vaccines
PROTECT
SARS-COV-2 infection
siRNA-LNP
Spread
System
therapeutic
Therapeutics
translation
treat
Treatment
University of Pennsylvania
utility
Vaccine
[DOI] 10.3390/pharmaceutics14020398 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/pharmaceutics14020398 PMC 바로가기 [Article Type] Review
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
Research Article
[키워드] age and gender
antibodies
antibody
antibody kinetics
Antibody Response
average
binding domain
BNT162b2
BNT162b2 vaccine
changes in
clinically
clinician
Cohort
COVID-19
COVID-19 pandemic
defined
difference
dosage
dose regimen
elicited
first dose
Follow-up
human cell
IgG
IgG antibody
IgG response
immune system
immunization
immunosuppressive drugs
linear
Moderna
mRNA
mRNA platform
mRNA vaccine
mRNA-1273
mRNA-1273 vaccine
overcome
participant
peaked
Pfizer/BioNTech
powerful tool
Prospective
regimens
regression modeling
remained
response
S-protein
SARS-CoV-2
SARS-CoV-2 vaccine
second dose
seroconverted
serological
Serologically
seronegative participants
significantly higher
Spike protein
the SARS-CoV-2
the vaccine
titer
translated
vaccination
Vaccine
Vaccines
virus spike protein
was used
were measured
[DOI] 10.1128/Spectrum.01162-21 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1128/Spectrum.01162-21 PMC 바로가기 [Article Type] Research Article
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Review
[키워드] acute respiratory syndrome
Cambridge
caused
challenge
coronavirus
Coronavirus-2
country
COVID-19
disease
effective
Emergency use
ENhance
global pandemic
highly pathogenic
Mainz
Moderna
MOST
mRNA platform
mRNA vaccine
mRNA-based vaccine
New York
Pfizer
Research
RNA vaccine
SARS-CoV-2
Spread
stability
storage
temperature
USA
vaccination
Vaccine
Vaccines
[DOI] 10.3390/vaccines9091033 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/vaccines9091033 PMC 바로가기 [Article Type] Review
Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
SARS-CoV-2 백신을 위한 mRNA 플랫폼의 긍정적인 측면
Article
[키워드] assumed
BNT162b1
causative agent
clinical trial
clinical trials
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 mRNA vaccine
COVID-19 mRNA vaccines
COVID-19 vaccines
develop
effective
Effective vaccines
Efficacy
host genome
humans
imperative
individual
lack
mechanism
mechanism of action
media
Messenger RNA
misinformation
modify
mRNA
mRNA platform
mRNA vaccine
mRNA-1273
mRNA-based COVID-19 vaccine
offer
Pfizer
raised
receiving
Safe
SARS-CoV-2
SARS-CoV-2 vaccine
skepticism
skepticism.
social media
Strains
vaccination
vaccination against COVID-19
Vaccine
Vaccine hesitancy
vaccine platform
[DOI] 10.1080/21645515.2021.1900713 PMC 바로가기 [Article Type] Article
[DOI] 10.1080/21645515.2021.1900713 PMC 바로가기 [Article Type] Article
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models
Article
[키워드] addition
animal model
approaches
Biotechnology
candidate
clinical development
coronavirus disease
COVID
COVID-19
COVID-19 vaccine
Diseases
effective vaccine
Efficacy
effort
elicit
elicited
Emergency
furin
glycoprotein
GSAS
hamsters
hypothetical
immunogenicity
immunology
Lung pathology
macaques
mice
Microbiology
mitigate
mRNA
mRNA platform
mRNA vaccine
mutant
NAb
Neutralization assay
neutralizing antibody
NHP
non-human primate
offer
pandemic
Pathogenesis
pre-fusion
Respiratory disease
response
responses
S-protein
SARS-CoV-2
selected
tested
Vaccine
vaccine candidate
Viral variants
weight loss
wild type
[DOI] 10.1038/s41541-021-00324-5 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41541-021-00324-5 PMC 바로가기 [Article Type] Article
The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland
Article
[키워드] Ad26.COV2.S
age
Allergic reactions
approach
approved
Attitude
AZD1222
BNT162b
BNT162b2
clinical trials
conducted
contrary
COVID-19
COVID-19 vaccination
COVID-19 vaccine
cross-sectional
CureVac
Effect
effective
eight
European
expressing
highest
inactivated
individual
information
Live attenuated vaccines
median
Moderna
mRNA platform
mRNA vaccine
mRNA vaccines
mRNA-1273
Novavax
NVX-CoV2373
pandemic
participant
Perception
Poland
POLE
produced
receive
risk
SARS-CoV-2
seeking
severe adverse event
Stage
union
vaccination
vaccination against COVID-19
Vaccinations
Vaccine
Vaccine hesitancy
Vaccines
vector vaccines
[DOI] 10.3390/vaccines9040382 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/vaccines9040382 PMC 바로가기 [Article Type] Article